Montair 10 mg Cipla
| Features | |
| Active substance | Montelukast |
| Also known as | Singulair |
| Blood pressure | No significant effects on blood pressure |
| Chemical name | 1-(((1R)-1-[(3E)-3-[(1E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl)methyl)cyclopropaneacetic acid |
| Dosage (medical) | Typically 10 mg once daily for adults and 4-5 mg for children |
| Dosage (sports) | Not applicable |
| Effects | Decreases bronchoconstriction and inflammation in asthma |
| Formula | C35H36ClNO3S |
| Half-life | 2.7–5.5 hours |
| Hepatotoxicity | Rare, but cases of drug-related liver injury reported |
| Lab Test | Not typically required for monitoring |
| Main action | Reduces inflammation and bronchoconstriction |
| Side effects | Headache, abdominal pain, thirst, dizziness, fatigue |
| Storage conditions | Store at 20В°C to 25В°C (68В°F to 77В°F) |
| Strength | 10mg |
| Substance class | Leukotriene receptor antagonist |
| Trade name | Singulair |
| Use in sports | Not traditionally used in sports for performance enhancement |
| Water Retention | No significant water retention |
| Manufacturer | Cipla Ltd. |
| Packing | 15 tabs/blister |